Patent Reviews Gave Innovators Headaches In 2015; Will Relief Come This Year?
Executive Summary
Inter partes review process picked up steam as generic manufacturers, biosimilar sponsors, and hedge fund manager Kyle Bass filed slew of petitions challenging validity of drug patents.